Navigation Links
Drive Long-Term Silencing with CMV Vectors


Ambion's newest line of plasmid siRNA expression vectors, pSilencer 4.1-CMV, feature polymerase (pol) II promoters that drive transcription of both an siRNA template and an antibiotic resistance gene. The CMV promoter is used to drive siRNA expression. This strong promoter is active in a broad range of cell types and performs better than most pol III promoters under long term selection.

One use of plasmid-based siRNA expression vectors is for long term gene silencing studies in mammalian cells. Typically these vectors encode a hairpin siRNA under the control of a polymerase III promoter and an antibiotic resistance gene driven by a polymerase II promoter. While it is possible to use such vectors to produce stable cell lines expressing siRNAs that silence their targets, there are, to date, very few published accounts of doing so (Xia 2002). One explanation for the difficulty in producing such clones is possible interference between the pol II and III promoters. Although the exact mechanism is not understood, it is hypothesized that when pol II and III promoters are in close proximity, interference of transcription between the two promoters can occur. This suggests that clones derived from a transfection/selection experiment will either express the siRNA or the antibiotic resistance gene but rarely express both. To overcome this potential problem, we have constructed three pSilencer 4.1-CMV siRNA Expression Vectors that express a hairpin siRNA as well as an antibiotic resistance gene from pol II promoters. The CMV promoter expresses the siRNA, and an SV40 promoter expresses the antibiotic resistance gene. To demonstrate the utility of these CMV promoter vectors, the vectors were engineered to express an siRNA targeting GAPDH. The vectors were then transfected into HeLa cells, which were in turn put under long term antibiotic selection. This strategy produced cell lines that have had reduced levels of GAPDH mRNA and protein for over 8 months.

As shown in Figure 1, several pSilencer 4.1-CMV transfected clones had reduced GAPDH protein and mRNA expression compared to non-transfected HeLa cells. Panel B shows immunofluorescence data demonstrating the relative fluorescence differences between a clone with reduced levels of GAPDH versus a clone that did not show significant GAPDH reduction.

Figure 1. Long Term Stable Reduction in GAPDH Levels. Both mRNA expression levels and protein levels were analyzed in these same clones using either real-time PCR or immunofluorescence analysis. (A) Clones that showed low levels of GAPDH protein expression also showed low levels of GAPDH mRNA expression. (B) Representative immunostaining data showing the relative fluorescence differences between a clone having GAPDH reduced and another clone that did not have a significant amount of GAPDH knocked down. Immunofluorescence was performed using gene specific primary antibodies and a fluorescein conjugated secondary antibody and the resulting reduction in protein expression was examined by fluorescence microscopy. The cells were mounted with DAPI to stain nuclei (Blue). Images were digitally captured and quantified using Metamorph software.


The pSilencer 4.1-CMV siRNA Expression Vectors are provided with 1) linearized and purified vector ready for ligation; 2) a DNA insert encoding a GAPDH-specific siRNA; 3) a circular, negative control pSilencer vector that expresses a scrambled control siRNA; and 4) 1X DNA Annealing Solution.


back to top


Ordering Information
Cat# Product Name Size 5775 pSilencer 4.1-CMV puro 20 rxns 5777 pSilencer 4.1-CMV hygro 20 rxns 5779 pSilencer 4.1-CMV neo 20 rxns 5790 pSilencer adeno 1.0-CMV System 5 virus preparations
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Optimization of Biolistic Transformation Using the Helium-Driven PDS-1000/He System
2. Long-Term Instrument Control and Connectivity Solutions
3. RNAi Gene Silencing System
4. Quantification of siRNA Silencing Efficiency Using the LightCycler System
5. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
6. Enhanced siRNA Delivery and Long-term Gene Silencing
7. Fast, Accurate Assessment of siRNA-induced Gene Silencing
8. Superior Gene Silencing Using Adenoviral Vectors
9. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
10. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
11. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drive Long Term Silencing with CMV Vectors

(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
(Date:3/25/2015)... market is one of the most attractive in the ... plus a growing economy and increasing government investment in ... The Russian market is set to grow at twice ... estimates around 10-15% annually reaching an approximate market value ... Cross Green Cross provides total healthcare solutions ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... AAFS Convention -- With,tomorrow,s release of the Forensics ... Forensic Science Organizations (CFSO) has announced that: , ... be available to the media for comment,on the Forensics ... of,Sciences on Wednesday, February 18th at 1:00 pm EST. ...
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... the treatment of human viral and other infectious diseases, today ... ended December 31, 2008. At December 31, 2008, Idenix,s cash, ... , , ...
... Even Among Companies Doing Well, Relationships Weaken in Many CountriesNEW ... physicians in four out of the five major European countries ... top marks for effectively delivering key sales and service activities. ... ties with Novartis in the UK and Germany. In ...
Cached Biology Technology:CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 2Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 3Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 4Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 5Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 6Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 7
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... expects to fund some 240 top researchers in its ... of grantees follows the 299 researchers who received grants ... In total, 2503 proposals were submitted to the second ... is studying the kidney glomerular ultrafiltration in both health ...
... for Microbiology (ASM) today announced plans to launch mBio ... microbiology research broadly accessible, in mid-2010. The focus of ... spanning the entire spectrum of microbiology and related fields. ... interconnected one in which microbes interact with living and nonliving ...
... circumpolar Arctic research focuses on the physical, direct changes ... and temperature increases. "What,s understudied is the living component ... "Donie" Bret-Harte, associate professor of biology at the University ... be published September 11, 2009 in the journal ...
Cached Biology News:ERC Starting Grant for the researcher of kidney diseases 2American Society for Microbiology to launch new open-access journal 2Scientists seek new emphases in Arctic climate change research 2
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... Development kit contains the basic components required ... measure natural and recombinant Feline IL-10 in ... contains sufficient materials to run ELISAs on ... following conditions are met: The assay ...
Biology Products: